Lumos Diagnostics share price rockets 1,036% in 2 days on FDA news

Investors are sending the Lumos Diagnostics share price through the roof following news from the US Food and Drug Administration.

| More on:
Man pointing at a blue rising share price graph.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Lumos Diagnostics Holdings Ltd (ASX: LDX) share price is going through the roof!

Shares in the ASX healthcare stock closed on Friday trading for 1.1 cents. At the time of writing, shares are swapping hands for 12.5 cents.

Shares gained 564% in Monday trade. And they're up another 71% in morning trade today.

That sees the Lumos Diagnostics up a stellar 1,036% in less than two days of trading!

This comes after Lumos, which develops and sells point-of-care diagnostic (POC) tests, reported it had received clearance from the United States Food and Drug Administration (FDA) for one of its core products.

Here are the highlights.

What's happening with the FDA?

Investors are bidding up the Lumos Diagnostics share price after the company received FDA clearance to market its FebriDx rapid, point-of-care test in the US.

FebriDx can now be marketed in the world's top economy to assist healthcare professionals in diagnosing bacterial acute respiratory infections and differentiating this from non-bacterial etiology in urgent care and emergency situations.

FebriDx is already registered in the United Kingdom, Europe, Canada, the United Arab Emirates, Brazil, Turkey, Pakistan, Singapore, Malaysia and Australia.

Lumos Diagnostics noted FebriDx can help combat the overuse of antibiotics, which is contributing to resistant strains of bacteria. The company said most acute respiratory infections are viral in origin, yet antibiotics are commonly prescribed. Up to 40% of these prescriptions are considered unnecessary.

Commenting on the FDA approval sending the Lumos Diagnostics share price rocketing, CEO Doug Ward said, "We are delighted to finally secure clearance to market our FebriDx rapid, point-of-care test in the US as we continue to believe it has an important role to play in antibiotic stewardship."

Ward added:

With this clearance in hand, we anticipate securing our first commercial orders in the US before the end of calendar year 2023. In the meantime, we are continuing to work with distribution partners and potential licensees, as well as establish our own focused sales effort, as we prepare to launch FebriDx in the US.

How has the Lumos Diagnostics share price performed longer term?

While you won't hear any recent investors complaining following this week's surge, the Lumos Diagnostics share price remains down 17% over the past 12 months.

The ASX healthcare share has gained 160% in 2023.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »